PL3768709T3 - Analizy mikroczipowej elektroforezy kapilarnej i stosowane w nich odczynniki - Google Patents

Analizy mikroczipowej elektroforezy kapilarnej i stosowane w nich odczynniki

Info

Publication number
PL3768709T3
PL3768709T3 PL19714055.1T PL19714055T PL3768709T3 PL 3768709 T3 PL3768709 T3 PL 3768709T3 PL 19714055 T PL19714055 T PL 19714055T PL 3768709 T3 PL3768709 T3 PL 3768709T3
Authority
PL
Poland
Prior art keywords
capillary electrophoresis
reagents used
electrophoresis analysis
microchip capillary
microchip
Prior art date
Application number
PL19714055.1T
Other languages
English (en)
Inventor
Timothy Riehlman
Gabriel Carreau
Jeffrey Schneiderheinze
Nicole M. Nall
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL3768709T3 publication Critical patent/PL3768709T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44743—Introducing samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44747—Composition of gel or of carrier mixture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Electrochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19714055.1T 2018-03-19 2019-03-15 Analizy mikroczipowej elektroforezy kapilarnej i stosowane w nich odczynniki PL3768709T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644933P 2018-03-19 2018-03-19
PCT/US2019/022525 WO2019182901A1 (en) 2018-03-19 2019-03-15 Microchip capillary electrophoresis assays and reagents

Publications (1)

Publication Number Publication Date
PL3768709T3 true PL3768709T3 (pl) 2024-05-20

Family

ID=65952203

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19714055.1T PL3768709T3 (pl) 2018-03-19 2019-03-15 Analizy mikroczipowej elektroforezy kapilarnej i stosowane w nich odczynniki

Country Status (21)

Country Link
US (1) US11054389B2 (pl)
EP (2) EP4317959B1 (pl)
JP (4) JP7315565B2 (pl)
KR (3) KR102777672B1 (pl)
CN (2) CN119335032A (pl)
AR (1) AR117402A1 (pl)
AU (2) AU2019239633B2 (pl)
BR (1) BR112020015291B1 (pl)
CA (2) CA3246952A1 (pl)
DK (1) DK3768709T3 (pl)
EA (1) EA202092203A1 (pl)
ES (1) ES2969882T3 (pl)
FI (1) FI3768709T3 (pl)
HU (1) HUE065344T2 (pl)
IL (2) IL277264B2 (pl)
MX (2) MX2020009696A (pl)
MY (1) MY202358A (pl)
PL (1) PL3768709T3 (pl)
SG (1) SG11202007011YA (pl)
TW (3) TWI913830B (pl)
WO (1) WO2019182901A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CA3246952A1 (en) 2018-03-19 2025-10-31 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11835527B2 (en) * 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
BR112023024984A2 (pt) * 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
MX2024005090A (es) 2021-10-26 2024-07-19 Regeneron Pharma Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
CN121925272A (zh) 2023-09-29 2026-04-24 瑞泽恩制药公司 利用受控成核进行冻干
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127134A (en) 1995-04-20 2000-10-03 Carnegie Mellon University Difference gel electrophoresis using matched multiple dyes
WO1999033861A1 (en) * 1997-12-31 1999-07-08 University Of Texas Systems Improved telomerase extraction method
WO1999060017A2 (en) 1998-05-18 1999-11-25 University College London Human tumour-derived polypeptide hormone phosphatonin
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2002095356A2 (en) * 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Methods and compositions for analyzing proteins
JP2003114216A (ja) * 2001-10-05 2003-04-18 Advance Co Ltd 電気泳動装置
BR0307907A2 (pt) * 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
JP2006508907A (ja) 2002-07-26 2006-03-16 アクララ バイオサイエンシーズ， インコーポレイテッド 親油性電気泳動プローブ
DE10258150A1 (de) 2002-12-10 2004-07-08 Dyomics Gmbh Hydrophile Marker auf der Basis von Benzopyrylo-Polymethinen
AU2003903317A0 (en) * 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
ATE546734T1 (de) * 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
WO2006020498A2 (en) * 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
US20070141637A1 (en) 2004-11-15 2007-06-21 Shima David T Marker for fenestrae
EP1801573A1 (en) 2005-12-21 2007-06-27 Boehringer Mannheim Gmbh Method and apparatus for parallel two-dimensional electrophoresis
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
ES2426069T3 (es) * 2007-02-12 2013-10-21 A1M Pharma Ab Diagnóstico de preeclampsia
EP2158328B1 (en) * 2007-05-18 2014-01-01 Life Technologies Corporation Rapid protein labeling and analysis
BRPI0813985B1 (pt) 2007-07-31 2022-05-10 Regeneron Pharmaceuticals, Inc Anticorpos humanos ou fragmentos de ligação a antígenos, composição farmacêutica dos mesmos e método para produzir um anticorpo anti-cd20 humana ou fragmento de ligação a antígeno de um anticorpo
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
NZ592436A (en) * 2008-11-06 2012-10-26 Glenmark Pharmaceuticals Sa Treatment with anti-alpha2 integrin antibodies
KR20100053015A (ko) * 2008-11-12 2010-05-20 경희대학교 산학협력단 인간 골수성 백혈병 세포주에 세포사멸을 유도하는 나프타자린 유도체
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010078601A1 (en) 2009-01-05 2010-07-08 The Regents Of The University Of California High throughput biomolecule separation and analysis
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
CN102648415A (zh) * 2009-08-25 2012-08-22 生命技术公司 定量荧光蛋白标准品
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014055936A1 (en) * 2012-10-04 2014-04-10 Integenx Inc. Preservation of biological materials in non-aqueous fluid media
US10357538B2 (en) * 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
WO2014116596A1 (en) * 2013-01-22 2014-07-31 Abbvie, Inc. Methods for optimizing domain stability of binding proteins
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
KR20150127591A (ko) 2013-03-15 2015-11-17 리제너론 파아마슈티컬스, 인크. Il-33 길항제 및 이의 용도
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
BR112017005110A2 (pt) 2014-09-16 2018-01-23 Regeneron Pharma anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
CA3246952A1 (en) 2018-03-19 2025-10-31 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents

Also Published As

Publication number Publication date
CA3089655A1 (en) 2019-09-26
KR20230031987A (ko) 2023-03-07
TWI779177B (zh) 2022-10-01
US11054389B2 (en) 2021-07-06
KR102722812B1 (ko) 2024-10-29
JP7315565B2 (ja) 2023-07-26
ES2969882T3 (es) 2024-05-23
KR20240157124A (ko) 2024-10-31
TW202516175A (zh) 2025-04-16
MX2020009696A (es) 2020-10-07
US20190285580A1 (en) 2019-09-19
TWI913830B (zh) 2026-02-01
HUE065344T2 (hu) 2024-05-28
IL307577A (en) 2023-12-01
KR20200130821A (ko) 2020-11-20
JP7486637B2 (ja) 2024-05-17
IL307577B1 (en) 2025-02-01
CN111868085A (zh) 2020-10-30
JP2025156526A (ja) 2025-10-14
JP2024097873A (ja) 2024-07-19
TW202323813A (zh) 2023-06-16
EP4317959A3 (en) 2024-03-27
AU2019239633A1 (en) 2020-11-19
DK3768709T3 (da) 2024-01-29
CA3246952A1 (en) 2025-10-31
KR102503356B1 (ko) 2023-02-24
EP3768709A1 (en) 2021-01-27
AR117402A1 (es) 2021-08-04
EP4317959B1 (en) 2026-04-29
BR112020015291A2 (pt) 2020-12-08
WO2019182901A1 (en) 2019-09-26
IL277264A (en) 2020-10-29
IL277264B1 (en) 2023-11-01
JP7724903B2 (ja) 2025-08-18
AU2026201984A1 (en) 2026-04-02
AU2019239633B2 (en) 2025-12-18
EP3768709B1 (en) 2023-12-27
MX2024012221A (es) 2024-11-08
EA202092203A1 (ru) 2020-12-07
IL277264B2 (en) 2024-03-01
KR102777672B1 (ko) 2025-03-10
CN119335032A (zh) 2025-01-21
FI3768709T3 (fi) 2024-02-01
JP2021516334A (ja) 2021-07-01
JP2023093664A (ja) 2023-07-04
TWI854343B (zh) 2024-09-01
BR112020015291B1 (pt) 2023-09-26
CA3089655C (en) 2026-01-20
TW202004178A (zh) 2020-01-16
MY202358A (en) 2024-04-24
IL307577B2 (en) 2025-06-01
SG11202007011YA (en) 2020-08-28
CN111868085B (zh) 2024-11-05
EP4317959A2 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
DK3768709T3 (da) Mikrochip-kapillærelektroforese-assays og reagenser
IL283416A (en) Genomic infrastructure for on-site or cloud-based dna and rna processing and analysis
DK3916108T3 (da) Fremgangsmåde til rumlig tagging og analyse af nukleinsyrer i en biologisk prøve
EP4190890A4 (en) NUCLEIC ACID MICROFLUIDIC DETECTION KIT AND DETECTION DEVICE
EP3766988C0 (en) HIGH THROUGHPUT ANALYSIS OF SINGLE CELLS COMBINING PROTEOMIC AND GENOMIC INFORMATION
DK3882357T3 (da) Fremgangsmåder og sammensætninger til analyse af nukleinsyrer
DK3411151T3 (da) Mikrofluidt assaysystem og fremgangsmåde til at udføre et assay
EP3828281C0 (en) METHODS FOR DETECTING CPG METHYLATION OF TUMOR-DERIVED DNA IN BLOOD SAMPLES
IL290274A (en) Methods and reagents for nucleic acid sequencing and associated applications
DK3746225T3 (da) Analytiske systemer og fremgangsmåder
SI3491025T1 (sl) Protitelesa fcrn in njihovi načini uporabe
HUE048752T2 (hu) Mintabefogadó elem, analizálókészlet és eljárás egy folyadék, különösen egy hûtõ-kenõanyag emulzió elemzésére
EP3607326A4 (en) METHODS AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES
EP3570980A4 (en) PROCESSES AND DEVICES FOR THE ANALYSIS OF SAMPLES
DK3290441T3 (da) Rgma-bindingsprotein og anvendelse deraf
EP3815094A4 (en) NUCLEIC ACID INTEGRATION AND REARRANGEMENT ANALYSIS
EP3516386A4 (en) PROCESSES AND APPARATUS FOR MITIGATION OF CURRENT INVERSION IN HAIR ZONE ELECTROPHORESIS ELECTRONEBULIZATION DEVICES
DK3144682T3 (da) Analysechip og prøveanalyseindretning
PL3655540T3 (pl) Sposoby i urządzenia do określania na podstawie kwasów nukleinowych stanów chorobowych w czasie rzeczywistym
EP3589942A4 (en) IMPRESSION TAKING AND ANALYSIS OF PRECIOUS STONES
EP3477313A4 (en) POWER ANALYSIS METHOD AND DEVICE
DK3207374T3 (da) Fremgangsmåde og system til bestemmelse af koncentrationen af en analyt i en fluidprøve
IL271237A (en) Image capillary isoelectric focusing to analyze protein variants in a sample matrix
EP3630342A4 (en) METHODS AND SYSTEMS FOR SAMPLE ANALYSIS
EP3594674A4 (en) ELECTROPHORETIC ANALYSIS PROCESS, ELECTROPHORETIC ANALYSIS DEVICE AND ELECTROPHORETIC ANALYSIS PROGRAM